Director/PDMR Shareholding

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Cambridge, UK and Indianapolis, US – 13 October 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that on 12 October 2020, the Company's Employee Benefit Trust ("EBT") transferred 60,000 ordinary shares of 0.2 pence in the Company (the "Ordinary Shares") to Gary Gemignani following the vesting of share awards granted under the Company's Performance Share Plan.

Following the transfer of the Ordinary Shares referred to above. Gary Gemignani holds 60,000 Ordinary Shares, representing 0.07 per cent. of the total issued share capital of the Company.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Gary Gemignani
2	Reason for the notification
a)	Position/status	Chief Financial Officer/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Acacia Pharma Group plc
b)	LEI	213800SLDKXWKT6E3381
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of £0.02 each GB00BYWF9Y76
b)	Nature of the transaction	Allotment of Ordinary Shares following vesting of share award under the Company's Performance Share Plan
c)	Price(s) and volume(s)	60,000 Ordinary Shares at a price of £0.02 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	12 October 2020
f)	Place of the transaction	Euronext Brussels (XBRU)

Contacts

Acacia Pharma Group plc Mike Bolinder, CEO Gary Gemignani, CFO +44 1223 919760 / +1 317 505 1280 IR@acaciapharma.com	International Media Mark Swallow, Frazer Hall, David Dible Citigate Dewe Rogerson +44 20 7638 9571 acaciapharma@citigatedewerogerson.com
US Investors LifeSci Advisors Irina Koffler +1 917-734-7387 ikoffler@lifesciadvisors.com	Media in Belgium and the Netherlands Chris Van Raemdonck +32 499 58 55 31 chrisvanraemdonck@telenet.be